Compare Danaos Corporation (DAC) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaos Corporation vs Illumina, Inc. — how do they compare? Danaos Corporation trades at $129.89 (market cap $2.36B), while Illumina, Inc. trades at $191.2 (market cap $28.93B). The key difference: Illumina, Inc. is far larger — about 12.3× Danaos Corporation's market cap, and Danaos Corporation pays a 2.78% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| DAC | ILMN | |
|---|---|---|
Market Cap | $2.36B | $28.93B |
Sector | Technology | Health |
52-Week High | $134.63 | $194.33 |
52-Week Low | $84.05 | $91.00 |
Enterprise Value | $2.36B | $30.32B |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Illumina (ILMN) trades at $190.05, showing strong momentum with a 43.7% gain year-to-date and recent earnings beats. The stock is technically bullish, trading near resistance at $191 with solid fundamentals including 19.42% net margins and robust cash flow. Recent leadership appointments and product launches like StrataMap Spatial Solution highlight ongoing innovation in genomics sequencing.
Outlook remains positive driven by sequencing demand and margin expansion, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is bullish with 51% buy ratings, though the current price exceeds the $174.44 target, suggesting near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
